CYP3A4 and Other metabolic disease: Impaired drug metabolism, metabolic disorders, and competition for CYP3A4 with other drugs (e.g., statins) are possible mechanisms leading to a lower concentration of clopidogrel’s active metabolite and insufficient antiplatelet effects [34,35].